Top Abstract Purchase Related
Home
>
Node
>
Subnode

Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125

Sevelda, P.; Dittrich, C.; Salzer, H.; Pateisky, N.; Spona, J.

Cancer Detection and Prevention 9(5-6): 521-528

1986

ISSN/ISBN: 0361-090X
PMID: 3465442
Document Number: 284999
The cytotoxic efficacy of a new sequential chemotherapy, called changing-scheme (adriamycin/cisplatin-vincristine/cyclophosphamide-HD-methotrexate), was investigated parallel to the course of CA-125 serum levels. Sixty-three percent of the women studied achieved remission under this chemotherapy. A correlation between clinically proven tumor stage and CA-125 serum level was found in 90%. The cytotoxic potential of the three single parts of the changing-scheme was demonstrated based on decreasing CA-125 serum levels. The value of the tumor marker CA-125 for the follow-up of patients with malignant ovarian tumors is discussed in detail.

Document emailed within 1 workday
Secure & encrypted payments

Pizzocaro, G.; Milani, A.; Piva, L.; Faustini, M.; Spino, E. 1991: Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study European Urology 20(2): 89-92
Sleijfer, S.; Van der Graaf, W.T.; Willemse, P.H.; De Vries, E.G.; Schraffordt Koops, H.; Mulder, N.H. 1995: High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer Anticancer Research 15(3): 1039-1042
Konami, T.; Wakabayashi, Y.; Kim, T.; Ishida, A.; Arai, Y.; Konishi, T.; Pak, K.; Takeuchi, H.; Tomoyoshi, T.; Watanabe, J. 1989: Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II) and adriamycin in urothelial cancer Hinyokika Kiyo. Acta Urologica Japonica 35(2): 231-237
Ohara, N.; Teramoto, K. 2000: Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report Clinical and Experimental Obstetrics and Gynecology 27(2): 123-124
Deng, C.; Huang, R.; Lian, L. 1996: Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer Zhonghua Fu Chan Ke Za Zhi 31(3): 159-162
Rassweiler, J.; Rüther, U.; Bäuerle, K.; Bub, P.; Jipp, P.; Eisenberger, F. 1989: Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity Der Urologe. Ausg. a 28(1): 25-30
Wada, N.; Kobayashi, H.; Oka, S.; Ando, J.; Tamura, H. 2002: Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(11): 1935-1942
Ikeda, I.; Shuin, T.; Yao, M.; Kubota, Y.; Hosaka, M. 1993: New salvage chemotherapy (cisplatin, adriamycin, bleomycin, methotrexate, etoposide) for advanced nonseminomatous testicular cancer: experience in three cases Hinyokika Kiyo. Acta Urologica Japonica 39(3): 237-242
Abad-Esteve, A.; Rosell, R.; Moreno, I.; Fernández-Marcial, C.; Roselló, M.; Ribas Mundó, M. 1988: VP-16, vincristine, adriamycin and cyclophosphamide (EVAC) in patients with small-cell lung cancer Medicina Clinica 90(14): 569-572
Miller, A.B.; Klaassen, D.J.; Boyes, D.A.; Dodds, D.J.; Gerulath, A.; Kirk, M.E.; Levitt, M.; Pearson, J.G.; Wall, C. 1980: Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer Canadian Medical Association Journal 123(5): 365-371
Nakano, K.; Yamamoto, M.; Iwamoto, H.; Hiramoto, T. 2003: Daily low-dose cisplatin plus concurrent high-dose thoracic radiotherapy in elderly patients with locally advanced unresectable non-small-cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(9): 1283-1287
Ehrlich, C.E.; Einhorn, L.; Stehman, F.B.; Blessing, J. 1983: Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan--the Indiana University experience Clinics in Obstetrics and Gynaecology 10(2): 325-335
Huang, H.; Lian, L.; Huang, R. 1995: Response of ovarian endodermal sinus tumor to combination chemotherapy with cis-platinum, vincristine and bleomycin or vincristine, actinomycin and cyclophosphamide Zhonghua Fu Chan Ke Za Zhi 30(5): 265-269
Vogl, S.E.; Berenzweig, M.; Kaplan, B.H.; Moukhtar, M.; Bulkin, W. 1979: The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) Cancer Treatment Reports 63(2): 311-317
Adam, Z.; Elbl, L.; Vorlícek, J.; Hájek, R.; Tomíska, M.; Hejlová, N.; Králová, E.; Novotná, H. 1994: Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD) Vnitrni Lekarstvi 40(8): 506-512
Shimizu, Y.; Nakayama, K.; Seimiya, Y.; Yamakawa, Y.; Koi, S.; Yokosuka, K.; Teshima, H.; Chen, J.T.; Fujimoto, I.; Yamauchi, K. 1991: Treatment of advanced or recurrent cervical cancer by a new BOMP regimen consisting of bleomycin, vincristine, mitomycin-C, and low-dose consecutive cisplatin Nihon Sanka Fujinka Gakkai Zasshi 43(5): 549-556
Fennelly, D.W.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; O'Connor, K.; Curtin, J.P.; Crown, J.P.; Hoskins, W.J.; Spriggs, D.R. 1997: Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer Seminars in Oncology 24(1 Suppl 2: S2
Lauria, F.; Baccarani, M.; Fiacchini, M.; Frezza, R.; Gobbi, M.; Tura, S. 1978: 5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas Cancer Treatment Reports 62(8): 1193-1197
Cadman, E.C.; Glick, J.H.; Cross, J.; Horton, J.; Taylor, S.G. 1984: Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer Cancer Treatment Reports 68(6): 877-879
Hainsworth, J.D.; Wolff, S.N.; Stein, R.S.; Greer, J.P.; Cousar, J.B.; Greco, F.A. 1986: Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis Cancer Treatment Reports 70(8): 953-958